Improved prediction of fracture risk leveraging a genome-wide polygenic risk score.
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
03 02 2021
03 02 2021
Historique:
received:
29
07
2020
accepted:
22
01
2021
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Accurately quantifying the risk of osteoporotic fracture is important for directing appropriate clinical interventions. While skeletal measures such as heel quantitative speed of sound (SOS) and dual-energy X-ray absorptiometry bone mineral density are able to predict the risk of osteoporotic fracture, the utility of such measurements is subject to the availability of equipment and human resources. Using data from 341,449 individuals of white British ancestry, we previously developed a genome-wide polygenic risk score (PRS), called gSOS, that captured 25.0% of the total variance in SOS. Here, we test whether gSOS can improve fracture risk prediction. We examined the predictive power of gSOS in five genome-wide genotyped cohorts, including 90,172 individuals of European ancestry and 25,034 individuals of Asian ancestry. We calculated gSOS for each individual and tested for the association between gSOS and incident major osteoporotic fracture and hip fracture. We tested whether adding gSOS to the risk prediction models had added value over models using other commonly used clinical risk factors. A standard deviation decrease in gSOS was associated with an increased odds of incident major osteoporotic fracture in populations of European ancestry, with odds ratios ranging from 1.35 to 1.46 in four cohorts. It was also associated with a 1.26-fold (95% confidence interval (CI) 1.13-1.41) increased odds of incident major osteoporotic fracture in the Asian population. We demonstrated that gSOS was more predictive of incident major osteoporotic fracture (area under the receiver operating characteristic curve (AUROC) = 0.734; 95% CI 0.727-0.740) and incident hip fracture (AUROC = 0.798; 95% CI 0.791-0.805) than most traditional clinical risk factors, including prior fracture, use of corticosteroids, rheumatoid arthritis, and smoking. We also showed that adding gSOS to the Fracture Risk Assessment Tool (FRAX) could refine the risk prediction with a positive net reclassification index ranging from 0.024 to 0.072. We generated and validated a PRS for SOS which was associated with the risk of fracture. This score was more strongly associated with the risk of fracture than many clinical risk factors and provided an improvement in risk prediction. gSOS should be explored as a tool to improve risk stratification to identify individuals at high risk of fracture.
Sections du résumé
BACKGROUND
Accurately quantifying the risk of osteoporotic fracture is important for directing appropriate clinical interventions. While skeletal measures such as heel quantitative speed of sound (SOS) and dual-energy X-ray absorptiometry bone mineral density are able to predict the risk of osteoporotic fracture, the utility of such measurements is subject to the availability of equipment and human resources. Using data from 341,449 individuals of white British ancestry, we previously developed a genome-wide polygenic risk score (PRS), called gSOS, that captured 25.0% of the total variance in SOS. Here, we test whether gSOS can improve fracture risk prediction.
METHODS
We examined the predictive power of gSOS in five genome-wide genotyped cohorts, including 90,172 individuals of European ancestry and 25,034 individuals of Asian ancestry. We calculated gSOS for each individual and tested for the association between gSOS and incident major osteoporotic fracture and hip fracture. We tested whether adding gSOS to the risk prediction models had added value over models using other commonly used clinical risk factors.
RESULTS
A standard deviation decrease in gSOS was associated with an increased odds of incident major osteoporotic fracture in populations of European ancestry, with odds ratios ranging from 1.35 to 1.46 in four cohorts. It was also associated with a 1.26-fold (95% confidence interval (CI) 1.13-1.41) increased odds of incident major osteoporotic fracture in the Asian population. We demonstrated that gSOS was more predictive of incident major osteoporotic fracture (area under the receiver operating characteristic curve (AUROC) = 0.734; 95% CI 0.727-0.740) and incident hip fracture (AUROC = 0.798; 95% CI 0.791-0.805) than most traditional clinical risk factors, including prior fracture, use of corticosteroids, rheumatoid arthritis, and smoking. We also showed that adding gSOS to the Fracture Risk Assessment Tool (FRAX) could refine the risk prediction with a positive net reclassification index ranging from 0.024 to 0.072.
CONCLUSIONS
We generated and validated a PRS for SOS which was associated with the risk of fracture. This score was more strongly associated with the risk of fracture than many clinical risk factors and provided an improvement in risk prediction. gSOS should be explored as a tool to improve risk stratification to identify individuals at high risk of fracture.
Identifiants
pubmed: 33536041
doi: 10.1186/s13073-021-00838-6
pii: 10.1186/s13073-021-00838-6
pmc: PMC7860212
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Subventions
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Organisme : CIHR
ID : 409511
Pays : Canada
Organisme : Wellcome Trust
ID : 212946/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12026/2
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : CIHR
ID : 365825
Pays : Canada
Organisme : Medical Research Council
ID : MC_UU_00017/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137686851
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13049
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14135
Pays : United Kingdom
Références
JAMA. 2018 Jun 26;319(24):2521-2531
pubmed: 29946735
J Bone Miner Res. 2017 Feb;32(2):285-293
pubmed: 27649491
Can Assoc Radiol J. 2011 Nov;62(4):243-50
pubmed: 21852066
Eur J Epidemiol. 2011 Apr;26(4):261-4
pubmed: 21431839
JAMA. 1990 Feb 2;263(5):665-8
pubmed: 2404146
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Stat Med. 1984 Apr-Jun;3(2):143-52
pubmed: 6463451
J Natl Cancer Inst. 1988 Oct 5;80(15):1198-202
pubmed: 3047407
J Bone Miner Res. 2006 Apr;21(4):529-35
pubmed: 16598372
Nat Commun. 2020 Jul 31;11(1):3865
pubmed: 32737319
Nat Genet. 2012 Apr 15;44(5):491-501
pubmed: 22504420
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Postgrad Med J. 2007 Aug;83(982):509-17
pubmed: 17675543
Osteoporos Int. 2015 Jul;26(7):1979-87
pubmed: 25690339
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
PLoS Med. 2020 Jul 2;17(7):e1003152
pubmed: 32614825
Osteoporos Int. 2005 Mar;16(3):229-38
pubmed: 15618996
Nat Med. 2020 Apr;26(4):549-557
pubmed: 32273609
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
BMJ. 2018 Aug 29;362:k3225
pubmed: 30158200
Osteoporos Int. 2000;11(8):669-74
pubmed: 11095169
Int J Epidemiol. 2011 Dec;40(6):1652-66
pubmed: 22158673
J Bone Miner Res. 2015 Jan;30(1):184-94
pubmed: 25043339
Arch Osteoporos. 2017 Dec;12(1):43
pubmed: 28425085
Am J Epidemiol. 2005 Jan 15;161(2):180-5
pubmed: 15632268
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
J Bone Miner Res. 2017 Aug;32(8):1607-1614
pubmed: 28276592
Bone Rep. 2016 Jul 12;5:168-172
pubmed: 28580384
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Nature. 2017 Oct 19;550(7676):345-353
pubmed: 29019985
Clin Orthop Relat Res. 2014 Nov;472(11):3536-46
pubmed: 25091223
Lancet. 2002 Jun 1;359(9321):1929-36
pubmed: 12057569
J Bone Miner Res. 1996 Apr;11(4):530-4
pubmed: 8992884
PLoS One. 2018 Jul 26;13(7):e0200785
pubmed: 30048462
Nat Genet. 2019 Apr;51(4):584-591
pubmed: 30926966
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Bone Miner Res. 2013 Oct;28(10):2156-64
pubmed: 23572424
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Contemp Clin Trials. 2005 Oct;26(5):569-85
pubmed: 16084776
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
J Bone Miner Res. 2016 Apr;31(4):789-95
pubmed: 26572781
J Bone Miner Res. 2018 Mar;33(3):510-516
pubmed: 29220072
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 32067027
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Osteoporos Int. 2008 Oct;19(10):1395-408
pubmed: 18751937
Arch Osteoporos. 2016 Dec;11(1):25
pubmed: 27465509
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978
Nat Genet. 2019 Feb;51(2):258-266
pubmed: 30598549
Sci Rep. 2019 Apr 15;9(1):6086
pubmed: 30988369
Bioinformatics. 2015 Aug 1;31(15):2595-7
pubmed: 25810428